Our promise to you:
Guaranteed product quality, expert customer support.
24x7 CUSTOMER SERVICE
CONTACT US TO ORDER
Bcl2 Gene Editing 
Bcl2 (B-cell lymphoma 2) is a founding member of Bcl-2 family regulatory proteins (including Bcl-xL, Mcl1, Bcl-W, Bcl-B and Bcl2A1) that regulate apoptosis by inhibition ( anti-apoptosis) or induction (pro-apoptotic) apoptosis. Bcl2 is the second member of a series of proteins that originally described in chromosomal translocations, and involved chromosomes 14 and 18 in follicular lymphoma.
Bcl2 localizes to the outer membrane of mitochondria and plays an important role in promoting cell survival and inhibiting the role of pro-apoptotic proteins. Bcl2-like proteins can prevent the release of cytochrome C from mitochondria, and regulate the activation of several other caspases. Impaired Bcl2 gene has been identified as one of the causes of many cancers, including melanoma, breast cancer, prostate cancer, chronic lymphocytic leukemia, and lung cancer, also as one of the reasons for resistance to cancer treatment. Except cancers, researches show that Bcl2 is also involved in schizophrenia and autoimmunity.
Figure 1: The intrinsic and extrinsic pathway that lead to cell death (Aileen Chen. 2019)
To date, the use of small-molecule inhibitors has been the most successful strategy for targeting Bcl2 compared with peptide mimics and antisense oligonucleotides. In many SMIs progressed to clinical trials, ABT199 is the only successful BH3 generic drug clinically approved by the FDA. It is of great significance to research and develop new Bcl2 family inhibitors with good curative effects and to explore the combined effects of synergistic effects of these Bcl2 inhibitors with other known anticancer compounds.
Bcl2 Gene Editing Service
CRISPR/Cas9 PlatformCB, a global leading biotechnological company specializing in gene editing, is dedicated to offering comprehensive CRISPR/Cas9 gene editing services and products to a wide range of genomics researchers. Based on our platform, we can help you effectively control the genes you are interested deleted, inserted or point mutated in cells or animals via CRISPR/Cas9 technology.
- Bcl2 Gene Editing Cell Line Generation
With deep gene editing knowledge and extensive experience in experimental operation and data processing, we have successfully implemented Bcl2 CRISPR/Cas9 gene edited in both easy-to-transfect cell lines and hard-to-transfect cells. To support your projects, we will offer you full-length Bcl2 gene editing service from strategy design to final stable cells. Our Bcl2 gene editing cell line generation services include:
✧ Strategy design
✧ gRNA design and synthesis
✧ Transfect the cell lines you interest
✧ Select the high expression cells and sort monoclonal cell
✧ Validate the knockout/knockin/point mutation of Bcl2 by PCR and sequencing
✧ Produce cryogenic preserved vials of stable cells and a final report
Typically, we develop CRISPR-mediated gene editing cell lines including cancer cells, primer cells, etc. such as HEK239T, Hela, HepG2, U87, Ba/F3, CHO, MDA-MB-453, MDA-MB-231NIH3T3, T47D, Neuro2a, MCF7, RKO, K562, RAW264.7, etc.
Meanwhile, other host cell lines are available, tell us your requirements.
- BCL2 Gene Editing Animal Model Generation
CRISPR/Cas9 PlatformCB also has extensive experience in incorporating CRISPR system into animal models, which have been fully recognized by our clients. Tell us your projects’ needs, we provide a full-length Bcl2 CRISPR/Cas9 gene editing animal service and guarantee at least 2 founders or 3 F1 animals with shorter turnaround time and lower price. Our Bcl2 gene editing animal model generation services include:
➢ Bcl2 gene conventional knockout animals
➢ Bcl2 gene conditional knockout animals
➢ Bcl2 point mutation animals
➢ Bcl2 knockin animals
Alternative species: mouse, rat, rabbit, zebrafish, C. elegans, etc.
CRISPR/Cas9 PlatformCB is devoted to providing the best gene editing services and products for academic research, biotech research and pharmaceutical drug discovery with excellent quality management and quality assurance capacity. To accelerate the achievement of your research goals, our gene editing expert team provides you with custom CRISPR/Cas9 services for any specific gene to help you solve problems encountered during your research. There is no doubt that CRISPR/Cas9 PlatformCB will be your best partner to support your research.
Related Products at CRISPR/Cas9 PlatformCB
| CATALOG NO. | PRODUCT NAME | INQUIRY |
|---|---|---|
| CLKO-0592 | BCL2L2-PABPN1 KO Cell Lysate-HEK293T | Inquiry |
| CLKO-1506 | BCL2 KO Cell Lysate-HeLa | Inquiry |
| CLKO-1853 | BCL2L2 KO Cell Lysate-HeLa | Inquiry |
| CSC-RT1993 | BCL2L2 Knockout Cell Line-HeLa | Inquiry |
| CSC-RT1102 | Human BCL2L2-PABPN1 Knockout Cell Line-HEK293T | Inquiry |
| CSC-RT1659 | Human BCL2 Knockout Cell Line-HeLa | Inquiry |
References:
- Tsujimoto Y. et al. "Cloning of the chromosome breakpoint of neoplastic B cells with the t(14;18) chromosome translocation. Science. 1984; 226 (4678):1097–9.
- Cleary ML. et al. Cloning and structural analysis of cDNAs for bcl-2 and a hybrid bcl-2/immunoglobulin transcript resulting from the t(14;18) translocation. Cell. 1986. 47 (1):19–28.
- Ryan S. Soderquist and Alan Eastman. BCL2 inhibitors as anticancer drugs: a plethora of misleading BH3 mimetics. Mol Cancer Ther. 2016; 15(9):2011–2017.
- Suzanne Cory & Jerry M. Adams. The Bcl2 family: regulators of the cellular life-or-death switch. Nature Reviews Cancer. 2002; 2:647–656.
- Gudapureddy Radha & Sathees C.Raghavan. BCL2: A promising cancer therapeutic target. Biochimica et Biophysica Acta. 2017; 1868(1):309-314.
- Andreas Strasser & David L Vaux. Viewing BCL2 and cell death control from an evolutionary perspective. Cell Death Differ. 2018; 25(1): 13–20.
- Aileen Chen. et al. The Functional Role of Bcl-2 Family of Proteins in the Immune System and Cancer. Oncomedicine. 2019; 4:17-26.